Sanofi’s 340B Rebate Model: A Joint Effort to Reform Drug Pricing Practices

By Rene Pretorius

November 29, 2024

How can a rebate model reshape the 340B Drug Pricing Program to address inefficiencies and abuses? Sanofi has introduced a 340B rebate model as a potential solution to long-standing challenges within the program. The 340B Program enables eligible hospitals to purchase outpatient drugs at discounted prices, contingent upon serving a minimum percentage of low-income Medicare and Medicaid patients. However, recent changes proposed by pharmaceutical companies like Eli Lilly and Johnson & Johnsonfavoring rebates over point-of-purchase discounts—have sparked debates and drawn scrutiny from federal regulators. Sanofi’s initiative follows those of Eli Lilly and Johnson & Johnson with the aim to refine the program by tackling its inefficiencies.

Sanofi’s 340B Rebate Model

Sanofi has proposed a new 340B rebate model specifically to combat problems such as duplicate discounts and diversion. These practices have been criticized for benefiting entities that do not serve the vulnerable patients the program is meant to assist. By focusing on these issues, Sanofi’s 340B rebate model represents a significant step towards improved efficiency in the pharmaceutical sector.

Alignment with J&J and Eli Lilly

Sanofi’s initiative mirrors that of other pharmaceutical giants like Johnson & Johnson (J&J) and Eli Lilly. Both these companies have proposed their own rebate models addressing similar concerns. Here are some key points of alignment:

  • Addressing Abuse

All three companies (Sanofi, J&J, and Eli Lilly) are united in their focus on core issues: duplicate discounts and diversion. These practices lead to scenarios where entities claim rebates on prescriptions purchased at discounted 340B prices or provide 340B medicines to ineligible patients. With their rebate models, these Companies seek to eliminate these abuses and ensure that the program’s savings are directed towards the vulnerable populations it is designed to help.

  • Mechanism of the Model

Under Sanofi’s Credit Model, covered entities submit claims for 340B-eligible medicines through the 340B rebate model. This will enable Sanofi to pay the difference between the 340B price and the list price. This approach mirrors the models proposed by J&J and Eli Lilly, which also involve direct payment or rebate mechanisms. These models require entities to supply specific data confirming 340B eligibility, thus enhancing transparency and oversight within the system.

Industry-Wide Initiative

By aligning with J&J and Eli Lilly in proposing these rebate models, Sanofi is taking part in an industry-wide initiative to reform the 340B program. This coordinated effort demonstrates a broader commitment among pharmaceutical companies to ensure that safety net programs operate effectively and provide affordable care to vulnerable patients, rather than benefiting intermediaries.

Despite the positive intentions behind Sanofi’s 340B rebate model and those of its peers, criticisms have emerged from some 340B providers. These critics argue that the models could disrupt patient care and create additional administrative burdens. Sanofi and other companies assert that they design their rebate models to uphold the original intent of the 340B program. They also aim to introduce necessary checks and balances to ensure the program operates efficiently.

In summary, Sanofi’s 340B rebate model aligns closely with the initiatives of J&J and Eli Lilly. Its intent is to eliminate abuses, enhance transparency, and ensure that the program benefits the intended patient populations. This collective action highlights the industry’s effort to reform and strengthen the 340B program. It underscores its vital role in healthcare.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.